Mutual Funds Sahi Hai!
To avail the service, you will be redirected to loans.geojitcredits.com
Gland Pharma has received approval from the United States Food and Drug Administration (USFDA) for its Abbreviated New Drug Application filed for Methylprednisolone Acetate Injectable Suspension USP, 40 mg/mL and 80 mg/mL Single-Dose Vials and 200 mg/5 mL (40 mg/mL), 400 mg/10 mL (40 mg/mL), and 400 mg/5 mL (80 mg/mL) Multiple-Dose Vials.
The Product is bioequivalent and therapeutically equivalent to the reference listed drug (RLD), Depo-Medrol Injectable Suspension, 40 mg/mL and 80 mg/mL, of Pfizer Inc.
The Product is indicated for the treatment of Allergic States, Dermatologic Diseases, Endocrine Disorders, Gastrointestinal Diseases, Hematologic Disorders, Neoplastic Diseases, Nervous System, Ophthalmic Diseases, Renal Diseases, Respiratory Diseases, Rheumatic Disorders and Miscellaneous.
Ajay holds a bachelor’s degree in business administration from European University of Brussels, Belgium. Sahni has over 36 years of experience in FMCG & pharmaceutical industries. His expertise spans financial management, business development and general management.
Ajay in his previous leadership roles, was the managing director for Pinewood Healthcare, Ireland; managing director for Wockhardt Bio AG, Switzerland; president of Wockhardt France SAS and its subsidiaries.
He has a vast experience performing all kinds of roles including finance director, project manager- business development, director (financial control, planning and analysis), regional finance director for South and South-East Asia, president, and managing director in various companies viz., Sanofi SA, SanofiSynthelabo Inc., Sanofi-Synthelabo Pte., Ferring Pharmaceuticals, Wockhardt France SAS and multiple subsidiaries including Laboratoires Negma SAS, Wockhardt Bio AG. and Pinewood Healthcare.
Gland Pharma is a Hyderabad-based pharmaceutical company focused on generic injectables and ophthalmics. It operates in more than 60 countries under a business-to-business model and offers a broad portfolio of sterile injectable products, including vials, ampoules, pre-filled syringes, lyophilized vials, infusions, oncology and ophthalmic solutions.
The company’s consolidated net profit jumped 47.09% to Rs 316.96 crore in Q1 FY27 compared with Rs 215.48 crore in Q1 FY26. Revenue from operations climbed 19.57% YoY to Rs 1,800.27 crore in Q1 FY27.
The scrip 0.74% to settled at Rs 3097.50 on the BSE.
Gland Pharma Ltd gained for a fifth straight session today. The stock is quoting at Rs 3081.9, up 0.24% on the day as on 12:44 IST on the NSE. The benchmark NIFTY is up around 0.72% on the day, quoting at 23102.8. The Sensex is at 74685.25, up 0.72%. Gland Pharma Ltd has gained around 7.22% in last one month.
Meanwhile, Nifty Pharma index of which Gland Pharma Ltd is a constituent, has gained around 3.43% in last one month and is currently quoting at 26710.8, up 1.88% on the day. The volume in the stock stood at 89853 shares today, compared to the daily average of 3.98 lakh shares in last one month.
The PE of the stock is 35.92 based on TTM earnings ending June 26.
Gland Pharma Ltd is up for a third straight session today. The stock is quoting at Rs 3015.2, up 1.85% on the day as on 12:49 IST on the NSE. The benchmark NIFTY is down around 0.19% on the day, quoting at 22705.75. The Sensex is at 73291.61, down 0.42%. Gland Pharma Ltd has gained around 0.85% in last one month.
Meanwhile, Nifty Pharma index of which Gland Pharma Ltd is a constituent, has gained around 1.54% in last one month and is currently quoting at 26267.25, up 0.96% on the day. The volume in the stock stood at 1.19 lakh shares today, compared to the daily average of 4.37 lakh shares in last one month.
The PE of the stock is 34.6 based on TTM earnings ending June 26.
Gland Pharma Ltd dropped for a fifth straight session today. The stock is quoting at Rs 2833.6, down 0.59% on the day as on 13:19 IST on the NSE. The benchmark NIFTY is down around 1.24% on the day, quoting at 22406.15. The Sensex is at 72534.84, down 0.98%.Gland Pharma Ltd has lost around 2.2% in last one month.Meanwhile, Nifty Pharma index of which Gland Pharma Ltd is a constituent, has eased around 7.21% in last one month and is currently quoting at 25596.65, down 2.02% on the day. The volume in the stock stood at 2.88 lakh shares today, compared to the daily average of 4.04 lakh shares in last one month.
The PE of the stock is 33.4 based on TTM earnings ending June 26.
Gland Pharma Ltd gained for a third straight session today. The stock is quoting at Rs 3141.1, up 4.49% on the day as on 12:49 IST on the NSE. The benchmark NIFTY is down around 0.53% on the day, quoting at 22655.35. The Sensex is at 72805.99, down 0.36%. Gland Pharma Ltd has risen around 6.14% in last one month.
Meanwhile, Nifty Pharma index of which Gland Pharma Ltd is a constituent, has risen around 1.4% in last one month and is currently quoting at 26549.6, down 0.17% on the day. The volume in the stock stood at 8.23 lakh shares today, compared to the daily average of 4.76 lakh shares in last one month.
The PE of the stock is 35.13 based on TTM earnings ending June 26.
The Fed’s indication of another rate hike in 2026 is likely to keep investors cautious, particularly in rate-sensitive and foreign-portfolio-investment-driven segments. However, buying interest in select domestic sectors provided some support, the Nifty hovered above the 23,250 mark. Market participants are likely to track currency movements, US bond yields and foreign fund flows for further direction.
Pharma shares jumped after declining in the past five consecutive trading sessions.
At 13:27 IST, the barometer index, the S&P BSE Sensex jumped 51.75 points or 0.06% to 74,383.03. The Nifty 50 index added 53.65 points or 0.24% to 23,269.85.
The broader market outperformed frontline indices. The BSE 150 MidCap Index jumped 0.90% and the BSE 250 SmallCap Index rose 0.71%.
The market breadth was strong. On the BSE, 2,517 shares rose and 1,707 shares fell. A total of 235 shares were unchanged.
Trump Tariffs:
The US House of Representatives on Wednesday passed a Russia sanctions bill by 262-159 that gives President Donald Trump the power to impose tariffs of up to 100% on countries buying Russian oil and gas, directly targeting major importers such as India and China. The bill, which follows Senate approval on 7 August 2026, also expands sanctions on Russian officials, financial institutions and vessels linked to Russia's shadow fleet, while extending existing Iran sanctions by five years.
IPO Update:
National Stock Exchange of India (NSE) received bids for 2,98,19,560 shares as against 8,86,42,911 shares on offer, according to stock exchange data at 14:27 IST on 16 September 2026. The issue was subscribed 0.34 times.
The issue opened for bidding on 17 September 2026 and will close on 19 September 2026. The price band of the IPO is fixed between Rs 1,700 and 1,785 per share. An investor can bid for a minimum of 8 equity shares and multiples thereof.
Hero Motors received bids for 25,08,64,122 shares as against 8,86,07,596 shares on offer, according to stock exchange data at 14:27IST on 17 September 2026. The issue was subscribed 2.83 times.
The issue opened for bidding on 16 September 2026 and will close on 18 September 2026. The price band of the IPO is fixed between Rs 79 and 84 per share. An investor can bid for a minimum of 178 equity shares and multiples thereof.
Buzzing Index:
The Nifty Pharma index jumped 1.28% to Rs 26,480.80. The index declined 2.73% in the past five consecutive trading sessions
Alkem Laboratories (up 3.36%), Gland Pharma (up 3%), Aurobindo Pharma (up 2.88%), Dr Reddys Laboratories (up 2.81%), Laurus Labs (up 2.45%), Lupin (up 2.14%), Zydus Lifesciences (up 2%), Mankind Pharma (up 1.76%), Divis Laboratories (up 1.62%) and Biocon (up 1.54%) surged.
Numbers to Track:
The yield on India's 10-year benchmark federal paper fell 0.11% to 7.047 compared with the previous session close of 7.055.
In the foreign exchange market, the rupee edged lower against the dollar. The partially convertible rupee was hovering at 95.9200 compared with its close of 95.9100 during the previous trading session.
MCX Gold futures for 5 October 2026 settlement fell 0.64% to Rs 1,51,493.
The US Dollar Index (DXY), which tracks the greenback's value against a basket of currencies, was down 0.04% to 100.21.
The United States 10-year bond yield fell 0.32% to 4.988.
In the commodities market, Brent crude for the November 2026 settlement declined $1.40 or 1.32% to $104.43 a barrel.
Stock in Spotlight:
Semiconductor and electronics manufacturing stocks were in demand on Thursday, 17 September 2026, as SEMICON India 2026 got underway at Yashobhoomi in New Delhi. The three-day event is being held from 17 to 19 September under the theme 'Silicon to Systems: Building the Ecosystem'
Syrma SGS Technology was the top gainer, rising 7.11%. MosChip Technologies surged 4.95%, followed by Kaynes Technology India, which gained 4.71%. Dixon Technologies advanced 1.11%, while Avalon Technologies rose 1.07%.
Prime Minister Narendra Modi inaugurated SEMICON India 2026 on Thursday. The event brings together companies, policymakers, investors, researchers, startups and academic institutions from across the semiconductor and electronics value chain. The PMO said more than 600 companies and representatives from 52 countries are participating.
Gland Pharma Ltd gained for a third straight session today. The stock is quoting at Rs 2974.6, up 1.44% on the day as on 12:49 IST on the NSE. The benchmark NIFTY is down around 0.61% on the day, quoting at 23752.75. The Sensex is at 76008.11, down 0.66%. Gland Pharma Ltd has gained around 11.52% in last one month.
Meanwhile, Nifty Pharma index of which Gland Pharma Ltd is a constituent, has gained around 0.31% in last one month and is currently quoting at 26478.1, up 0.32% on the day. The volume in the stock stood at 6.85 lakh shares today, compared to the daily average of 9.69 lakh shares in last one month.
The PE of the stock is 34.25 based on TTM earnings ending June 26.
Gland Pharma Ltd, New India Assurance Company Ltd, Affle 3i Ltd, Titagarh Rail Systems Ltd are among the other stocks to see a surge in volumes on NSE today, 04 September 2026.
HBL Engineering Ltd saw volume of 127.24 lakh shares by 14:14 IST on NSE, a 20.33 fold spurt over two-week average daily volume of 6.26 lakh shares. The stock increased 4.20% to Rs.693.50. Volumes stood at 5.59 lakh shares in the last session.
Gland Pharma Ltd clocked volume of 26.88 lakh shares by 14:14 IST on NSE, a 9 times surge over two-week average daily volume of 2.99 lakh shares. The stock gained 1.61% to Rs.2,954.80. Volumes stood at 1.89 lakh shares in the last session.
New India Assurance Company Ltd witnessed volume of 588.98 lakh shares by 14:14 IST on NSE, a 8 times surge over two-week average daily volume of 73.61 lakh shares. The stock increased 17.69% to Rs.229.88. Volumes stood at 69.06 lakh shares in the last session.
Affle 3i Ltd clocked volume of 24.49 lakh shares by 14:14 IST on NSE, a 7.79 times surge over two-week average daily volume of 3.14 lakh shares. The stock gained 4.92% to Rs.1,593.90. Volumes stood at 13.26 lakh shares in the last session.
Titagarh Rail Systems Ltd saw volume of 27.15 lakh shares by 14:14 IST on NSE, a 7.34 fold spurt over two-week average daily volume of 3.70 lakh shares. The stock increased 2.53% to Rs.865.60. Volumes stood at 3.66 lakh shares in the last session.